Cochrane Review Group
Gynaecological, Neuro-oncology and Orphan Cancer
129 systematic reviews in Gynaecological, Neuro-oncology and Orphan Cancer ask 1,590 questions. 17.7% have no studies to answer them, 25.8% rest on very low certainty evidence and 25.5% reach moderate or high certainty.
Reviews
129
Questions
1,590
current versions
No studies
17.7%
Moderate or high
25.5%
No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 2 studies · 964 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 5 studies · 1968 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 6 studies · 2184 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 3 studies · 1222 participants | Very low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 129
Protons versus photons for the treatment of chordoma
CochraneSoF table
4 questions
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
CochraneSoF table
10 questions
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
CochraneSoF table
35 questions
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
CochraneSoF table
12 questions
Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis
CochraneSoF table
12 questions
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis
CochraneSoF table
43 questions
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
CochraneSoF table
34 questions
Green tea (Camellia sinensis) for the prevention of cancer
CochraneSoF table
22 questions
Telephone interventions for symptom management in adults with cancer
CochraneSoF table
5 questions
External beam radiation dose escalation for high grade glioma
CochraneSoF table
9 questions
Hormone replacement therapy after surgery for epithelial ovarian cancer
CochraneSoF table
8 questions
Anti‐epidermal growth factor receptor therapy for glioblastoma in adults
CochraneSoF table
7 questions
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer
CochraneSoF table
6 questions
Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis
CochraneSoF table
45 questions
Management of drainage for malignant ascites in gynaecological cancer
CochraneSoF table
6 questions
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
CochraneSoF table
13 questions
Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility
CochraneSoF table
4 questions
Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event
CochraneSoF table
13 questions
Dietary interventions for adult cancer survivors
CochraneSoF table
7 questions
Robot‐assisted surgery in gynaecology
CochraneSoF table
12 questions
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
CochraneSoF table
10 questions
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer
CochraneSoF table
3 questions
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer
CochraneSoF table
3 questions
Interventions to help support caregivers of people with a brain or spinal cord tumour
CochraneSoF table
6 questions
Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa)
CochraneSoF table
7 questions